Profile data is unavailable for this security.
About the company
Oxford Nanopore Technologies plc is engaged in the generation of molecular sensing technology based on nanopores. The Company has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.
- Revenue in GBP (TTM)169.67m
- Net income in GBP-154.51m
- Incorporated2005
- Employees1.24k
- LocationOxford Nanopore Technologies PLCOxford Science ParkGosling Building, Edmund Halley RoadOXFORD OX4 4DQUnited KingdomGBR
- Websitehttps://www.nanoporetech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CellaVision AB | 52.80m | 10.53m | 465.84m | 223.00 | 44.25 | 8.24 | 34.35 | 8.82 | 5.92 | 5.92 | 29.69 | 31.81 | 0.757 | 1.68 | 8.45 | 3,106,469.00 | 15.09 | 15.30 | 17.34 | 18.24 | 67.52 | 69.03 | 19.94 | 19.98 | 2.21 | 66.29 | 0.0688 | 110.18 | 5.94 | 13.17 | 10.12 | 8.00 | 30.45 | 8.45 |
Advanced Medical Solutions Group plc | 126.21m | 15.89m | 471.79m | 850.00 | 29.96 | 1.93 | 17.69 | 3.74 | 0.0724 | 0.0724 | 0.5755 | 1.12 | 0.4426 | 1.75 | 5.34 | 148,482.40 | 5.57 | 6.54 | 6.04 | 7.06 | 55.57 | 56.75 | 12.59 | 14.82 | 4.00 | -- | 0.0361 | 25.85 | 1.51 | 4.23 | -22.14 | -6.71 | 15.66 | 12.32 |
Stratec SE | 214.70m | 10.33m | 492.97m | 1.47k | 47.69 | 2.53 | 19.17 | 2.30 | 0.9991 | 0.9991 | 20.75 | 18.86 | 0.5906 | 1.34 | 5.11 | 165,771.40 | 2.84 | 7.07 | 3.55 | 8.20 | 25.60 | 27.32 | 4.81 | 9.70 | 0.8029 | 4.41 | 0.3826 | 40.81 | -4.63 | 6.88 | -55.29 | 3.30 | -2.16 | -7.68 |
medmix AG | 423.32m | 260.98k | 603.77m | 2.66k | 1,678.64 | 1.47 | 12.39 | 1.43 | 0.01 | 0.01 | 11.91 | 11.41 | 0.4606 | 3.65 | 6.05 | 183,070.00 | 0.0663 | 2.06 | 0.0846 | 2.49 | 32.41 | 36.38 | 0.1439 | 4.16 | 1.23 | 2.92 | 0.4244 | 67.70 | 1.99 | 1.40 | -97.41 | -64.36 | 12.01 | -- |
Paul Hartmann AG | 2.00bn | 24.19m | 610.51m | 10.17k | 25.12 | 0.6713 | 5.28 | 0.3049 | 8.00 | 8.00 | 662.57 | 299.40 | 1.18 | 2.02 | 5.72 | 231,438.00 | 1.64 | 3.87 | 2.26 | 5.34 | 56.01 | 56.71 | 1.39 | 2.98 | 1.16 | 4.87 | 0.1865 | 42.75 | 1.80 | 2.12 | -21.37 | -18.49 | 5.95 | 2.71 |
Revenio Group Oyj | 82.27m | 16.18m | 638.44m | 216.00 | 39.03 | 7.49 | 32.69 | 7.76 | 0.7205 | 0.7205 | 3.66 | 3.76 | 0.7069 | 5.50 | 7.60 | 447,574.10 | 13.90 | 14.33 | 16.77 | 17.90 | 51.01 | 50.73 | 19.66 | 21.13 | 1.79 | 28.49 | 0.1521 | 55.81 | -0.4125 | 25.80 | -12.15 | 18.72 | 17.67 | 6.30 |
Synsam AB (publ) | 448.39m | 25.94m | 657.49m | 3.52k | 25.15 | 3.37 | 8.06 | 1.47 | 2.34 | 2.34 | 40.45 | 17.46 | 0.7272 | 2.05 | 10.94 | 1,762,379.00 | 4.18 | -- | 5.85 | -- | 75.31 | -- | 5.75 | -- | 0.50 | -- | 0.5659 | -- | 11.90 | -- | -5.18 | -- | -- | -- |
El En SpA | 589.10m | 41.05m | 685.42m | 2.11k | 16.66 | 2.32 | 13.01 | 1.16 | 0.6038 | 0.6038 | 8.67 | 4.33 | 0.9515 | 2.04 | 4.05 | 332,511.90 | 6.88 | 7.43 | 12.83 | 13.52 | 39.14 | 38.83 | 7.23 | 7.63 | 1.20 | 232.14 | 0.164 | -- | 2.78 | 14.88 | -12.47 | 23.49 | -13.40 | -- |
Draegerwerk AG & Co KGaA | 2.85bn | 85.50m | 771.85m | 16.48k | 8.72 | 0.6117 | 3.61 | 0.2709 | 5.36 | 5.36 | 178.48 | 76.35 | 1.11 | 2.61 | 4.94 | 205,046.00 | 3.39 | 3.26 | 5.03 | 4.87 | 43.32 | 44.16 | 3.06 | 3.05 | 1.17 | 5.79 | 0.1662 | 11.38 | 10.78 | 5.39 | 271.05 | 33.87 | 2.64 | 55.73 |
Arjo AB (publ) | 827.53m | 38.61m | 877.57m | 6.71k | 24.36 | 1.56 | 7.60 | 1.06 | 1.90 | 1.90 | 40.76 | 29.72 | 0.6911 | 4.15 | 6.31 | 1,632,980.00 | 3.21 | 3.55 | 4.44 | 5.55 | 43.43 | 44.01 | 4.64 | 5.41 | 0.6913 | 4.14 | 0.4024 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
Medartis Holding AG | 184.43m | 538.50k | 903.63m | 829.00 | 1,567.62 | 3.71 | 48.05 | 4.90 | 0.0488 | 0.0488 | 17.33 | 20.63 | 0.6259 | 0.643 | 5.27 | 255,737.00 | 0.183 | 0.1919 | 0.2095 | 0.2153 | 79.04 | 82.33 | 0.2924 | 0.3542 | 1.59 | 1.46 | 0.1655 | 0.00 | 15.96 | 11.81 | 110.70 | -31.82 | 5.37 | -- |
Oxford Nanopore Technologies PLC | 169.67m | -154.51m | 925.55m | 1.24k | -- | 1.43 | -- | 5.46 | -0.1851 | -0.1851 | 0.2035 | 0.7493 | 0.212 | 0.8369 | 2.73 | 137,050.10 | -19.30 | -21.12 | -21.93 | -24.67 | 53.33 | 53.90 | -91.06 | -81.85 | 3.87 | -- | 0.0608 | -- | -14.57 | 39.15 | -69.74 | -- | 8.92 | -- |
GVS SpA | 361.37m | 17.48m | 987.30m | 4.39k | 58.40 | 3.34 | 17.74 | 2.73 | 0.1135 | 0.1135 | 2.38 | 1.99 | 0.4201 | 1.95 | 6.20 | 96,823.30 | 2.03 | 7.35 | 2.50 | 10.82 | 53.92 | 58.74 | 4.84 | 12.44 | 1.19 | 3.87 | 0.5709 | -- | 9.58 | 15.25 | -43.37 | -9.97 | 16.08 | -- |
Xvivo Perfusion AB | 47.93m | 7.49m | 1.03bn | 148.00 | 132.65 | 6.92 | 84.07 | 21.56 | 3.32 | 3.32 | 21.18 | 63.59 | 0.322 | 1.28 | 4.27 | 4,018,431.00 | 5.03 | 1.24 | 5.49 | 1.33 | 73.94 | 73.14 | 15.62 | 4.76 | 3.40 | -- | 0.0152 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
Biotage AB | 147.67m | 17.59m | 1.11bn | 669.00 | 61.58 | 3.81 | 36.81 | 7.49 | 3.01 | 3.01 | 25.57 | 48.61 | 0.5276 | 2.01 | 7.78 | 2,939,169.00 | 6.29 | 10.74 | 7.33 | 12.77 | 62.19 | 61.34 | 11.91 | 15.77 | 1.52 | 8.95 | 0.062 | 40.11 | 18.90 | 15.37 | -8.21 | 7.97 | 14.05 | 1.30 |
Embla Medical hf | 631.17m | 44.67m | 1.38bn | 4.00k | 30.80 | 2.40 | 16.26 | 2.19 | 0.9174 | 0.9174 | 12.95 | 11.77 | 0.5582 | 2.20 | 6.60 | 1,382,694.00 | 3.96 | 4.06 | 4.68 | 4.76 | 61.41 | 62.47 | 7.09 | 6.91 | 1.07 | 5.81 | 0.4325 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
Holder | Shares | % Held |
---|---|---|
Baillie Gifford & Co.as of 11 May 2023 | 41.71m | 4.85% |
Storebrand Asset Management ASas of 01 Apr 2024 | 35.29m | 4.10% |
Invesco Advisers, Inc.as of 28 Feb 2023 | 28.66m | 3.33% |
Lansdowne Partners (UK) LLPas of 28 Feb 2023 | 28.00m | 3.26% |
GIC Pte Ltd. (Investment Management)as of 27 Mar 2024 | 25.70m | 2.99% |
Redmile Group LLCas of 28 Feb 2023 | 24.70m | 2.87% |
The Vanguard Group, Inc.as of 01 Apr 2024 | 13.01m | 1.51% |
Aberforth Partners LLPas of 01 Apr 2024 | 11.13m | 1.29% |
Norges Bank Investment Managementas of 01 Apr 2024 | 9.42m | 1.10% |
Aegon Asset Management UK PLCas of 01 Apr 2024 | 7.14m | 0.83% |